image
By Asia Education Review Team , Saturday, 22 June 2024

ISTH Launches Global Educational Initiative on Factor XI/XIa Inhibitors

  •  The International Society on Thrombosis and Haemostasis (ISTH), a leading global not-for-profit organization, has officially launched a new educational program titled 'ISTH Emerging Therapies in Thrombosis Factor XI/XIa Inhibitors'. This initiative aims to enhance clinician awareness of factor XI (FXI) inhibition, potentially leading to the development of safer anticoagulation therapies.

    In early 2023, the ISTH established the multi-disciplinary, international Factor XI/XIa Educational Steering Committee. This group, led by Dr. Jeff Weitz, conducted a survey targeting a diverse audience to gather insights for the educational program. The committee used these survey results, along with input from other educational sources, to design a comprehensive educational roadmap for the multi-year initiative on factor XI/XIa inhibition.

    A central component of this initiative is the creation of a branded 'Learning Hub,' integrated within the ISTH Academy. This online platform provides Society members with access to premier educational resources. The Learning Hub will be unveiled at the ISTH's 2024 Congress in Bangkok, Thailand, from June 22-26, 2024. An in-person learning experience at the ISTH Academy booth will feature a 20-minute lecture on "The Promise of Factor XI/XIa Inhibitors: Anticoagulation Without the Risk of Bleeding", which will be recorded and made available on the ISTH Academy platform.

    Dr. Weitz, recently elected Secretary General of ISTH for the 2024-2028 term, expressed enthusiasm about the initiative, stating that the launch in Bangkok provides a unique opportunity to start this global education effort. He emphasized that feedback from the thrombosis and hemostasis community has been instrumental in shaping the educational content.

    The Learning Hub will offer a variety of resources, including the survey results, an educational roadmap, a glossary of terms, educational content developed by ISTH, links to external resources, and a research round-up featuring current trials and research on FXI/XIa inhibitors. Subscription-style updates will ensure that new research and educational activities are regularly provided to learners.